Retatrutide is not currently available outside clinical trials in the UK, but its blood pressure-lowering effects could interact with antihypertensive medicines and increase the risk of hypotension
Recently, the GIP/GLP-1R co-agonist tirzepatide has gone through several randomized controlled trials and was approved by the FDA for T2DM and obesity in 2022 and 2023, respectively
If a person is not consuming enough protein to replenish their amino acids which many who are on these weight loss drugs arent the body will start recycling muscle to make up for it
Understanding the current status helps patients make informed decisions
Accordingly, viral hijacking of NRP1 could exert chronic disorders of bone metabolism such as osteoporosis or osteopetrosis in PASC patients 116,117
While GLP-1 has been used successfully in treating diabetes and aiding in weight loss, GIP's potential is still being explored, particularly when used together with GLP-1